Abstract | BACKGROUND: Mucosal healing has been associated with long-term response to therapy for Crohn disease (CD). However, little is known about the significance of terminal ileum (TI) transmural thickness in predicting clinical outcomes. METHODS: In this retrospective observational cohort study, we examined the association of an index ultrasonographic assessment of TI thickness during the maintenance phase and the subsequent clinical outcome of CD in a cohort of patients treated with infliximab (IFX). Treatment failure was defined as treatment discontinuation because of lack of efficacy, a need for dose escalation, or surgery. Clinical response was defined as treatment continuation in the absence of any of the aforementioned failure criteria. RESULTS: Sixty patients with CD receiving IFX therapy were included in the study. The patients were followed for a median of 16 months (5-24 months) after an index intestinal ultrasound. Thirty-eight patients (63.3%) maintained response to the therapy and 22 patients (36.6%) failed the treatment, with a mean follow up of 10.5 months (6.5-17 months) vs 9.25 months (1-10.25 months), respectively. On univariate analysis, the only variables differing between treatment response and failure were a TI thickness of 2.8 vs 5 mm (P < 0.0001) and an IFX trough level of 6.6 vs 3.9 µg/mL (P = 0.008).On multivariable analysis, only a small bowel thickness of ≥4 mm was associated with the risk of treatment failure (odds ratio, 2.9; 95% CI, 1.49-5.55; P = 0.002). CONCLUSIONS: Our findings suggest that transmural thickness of ≥4 mm can predict subsequent treatment failure in patients with CD treated using IFX, indicating transmural thickness <4 mm as a potential novel valuable therapeutic target.
|
Authors | Ahmad Albshesh, Bella Ungar, Shomron Ben-Horin, Rami Eliakim, Uri Kopylov, Dan Carter |
Journal | Inflammatory bowel diseases
(Inflamm Bowel Dis)
Vol. 26
Issue 10
Pg. 1619-1625
(09 18 2020)
ISSN: 1536-4844 [Electronic] England |
PMID | 32860057
(Publication Type: Journal Article, Observational Study)
|
Copyright | © 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected]. |
Chemical References |
- Biomarkers
- Gastrointestinal Agents
- Infliximab
|
Topics |
- Adult
- Biomarkers
(analysis)
- Crohn Disease
(drug therapy, pathology)
- Drug Monitoring
(methods)
- Female
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Ileum
(pathology)
- Infliximab
(therapeutic use)
- Maintenance Chemotherapy
- Male
- Middle Aged
- Retrospective Studies
- Treatment Outcome
- Young Adult
|